KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Capital Expenditures: 2012-2025

Historic Capital Expenditures for Acadia Pharmaceuticals (ACAD) over the last 10 years, with Sep 2025 value amounting to $388,000.

  • Acadia Pharmaceuticals' Capital Expenditures rose 454.29% to $388,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $912,000, marking a year-over-year decrease of 23.49%. This contributed to the annual value of $523,000 for FY2024, which is 946.00% up from last year.
  • Acadia Pharmaceuticals' Capital Expenditures amounted to $388,000 in Q3 2025, which was down 14.35% from $453,000 recorded in Q4 2024.
  • Over the past 5 years, Acadia Pharmaceuticals' Capital Expenditures peaked at $1.1 million during Q1 2021, and registered a low of $1,000 during Q4 2021.
  • Over the past 2 years, Acadia Pharmaceuticals' median Capital Expenditures value was $388,000 (recorded in 2025), while the average stood at $303,667.
  • Its Capital Expenditures has fluctuated over the past 5 years, first plummeted by 99.95% in 2021, then spiked by 454.29% in 2025.
  • Quarterly analysis of 3 years shows Acadia Pharmaceuticals' Capital Expenditures stood at $1,000 in 2021, then reached $453,000 in 2024, then spiked by 454.29% to $388,000 in 2025.
  • Its Capital Expenditures was $388,000 in Q3 2025, compared to $453,000 in Q4 2024 and $70,000 in Q3 2024.